Connecting the dots: (RANKL+) extracellular vesicle count in blood plasma in relation to bone metastases, skeletal related events and osimertinib treatment in patients with EGFR mutated non-small cell lung cancer
No association was found between the presence of bone metastases and the total concentration of EVs, RANKL<sup>+</sup> EVs, or plasma values of RANKL and OPG. In patients without SREs the concentration of RANKL<sup>+</sup> EVs was significantly increased. Both the total EV and RANKL<sup>+</sup> EV concentrations significantly decreased during osimertinib treatment. This opens new perspectives for the role of (RANKL<sup>+</sup>) EVs as prognostic biomarkers for <i>EGFR</i> <sup>+</sup> NSCLC disease progression and response to therapy.
Authors
- C. Steendam (ORCID: https://orcid.org/0000-0002-8487-9344)
- Lizza Hendriks (ORCID: https://orcid.org/0000-0002-3521-2535)
- Wouter W. Woud (ORCID: https://orcid.org/0000-0003-1307-4458)
- Anne‐Marie C. Dingemans (ORCID: https://orcid.org/0000-0001-6105-182X)
- Sophie M. Ernst (ORCID: https://orcid.org/0000-0002-2070-3614)
- A. Brouns
- Liang Wu (ORCID: https://orcid.org/0000-0003-0294-7065)
- Marjolein van Driel
- Iris J. Robbesom-van den Berge
Institutions
- Erasmus MC (NL)
- Maastricht University (NL)
- Zuyderland Medisch Centrum (NL)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2025-03-01
- DOI
- https://doi.org/10.21037/tlcr-24-1007
- Citations
- 3
- Primary Topic
- Bone health and treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.14